NCT05174650 2025-12-05
Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
Clinical Trials
5 trialsNCT04087876 2025-04-06
Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations
Basilea Pharmaceutica
No longer available
NCT04604132 2024-04-04
FIDES-03
Basilea Pharmaceutica
Phase 1/2 Terminated
NCT03230318 2023-12-19
FIDES-01
Basilea Pharmaceutica
Phase 2 Completed
NCT01752920 2023-06-05
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
Basilea Pharmaceutica
Phase 1/2 Completed